end,filed,form,Name,Ticker,CIK,Currency,AccountsPayableCurrent,AccountsReceivableRelatedPartiesCurrent,AccruedLiabilitiesCurrent,AccruedProfessionalFeesCurrent,AccruedProfessionalFeesCurrentAndNoncurrent,AdditionalPaidInCapital,AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount,Assets,AssetsCurrent,Cash,CashAndCashEquivalentsAtCarryingValue,CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations,CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect,CommonStockParOrStatedValuePerShare,CommonStockSharesAuthorized,CommonStockSharesIssued,CommonStockSharesOutstanding,CommonStockValue,ConversionOfStockSharesConverted1,DeferredTaxAssetsGross,DeferredTaxAssetsOperatingLossCarryforwards,DeferredTaxAssetsOperatingLossCarryforwardsDomestic,DeferredTaxAssetsOther,DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost,DeferredTaxAssetsValuationAllowance,Dividends,EarningsPerShareBasicAndDiluted,EffectiveIncomeTaxRateContinuingOperations,EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate,EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance,EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther,EffectiveIncomeTaxRateReconciliationOtherAdjustments,EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized,FairValueAdjustmentOfWarrants,GeneralAndAdministrativeExpense,IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest,IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance,IncreaseDecreaseInAccountsPayable,IncreaseDecreaseInAccountsReceivableRelatedParties,IncreaseDecreaseInAccruedLiabilities,IncreaseDecreaseInDeferredCharges,IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets,InterestExpense,InterestPaidNet,InvestmentIncomeInterest,Liabilities,LiabilitiesAndStockholdersEquity,LiabilitiesCurrent,LiabilitiesFairValueAdjustment,NetCashProvidedByUsedInFinancingActivities,NetCashProvidedByUsedInOperatingActivities,NetIncomeLoss,NetIncomeLossAvailableToCommonStockholdersBasic,NonoperatingIncomeExpense,NotesPayableRelatedPartiesClassifiedCurrent,OperatingExpenses,OperatingLeasePayments,OtherGeneralAndAdministrativeExpense,OtherNonoperatingIncomeExpense,OtherPrepaidExpenseCurrent,OtherResearchAndDevelopmentExpense,PaymentsForRent,PaymentsForRepurchaseOfInitialPublicOffering,PaymentsForRepurchaseOfPreferredStockAndPreferenceStock,PreferredStockDividendsIncomeStatementImpact,PreferredStockParOrStatedValuePerShare,PreferredStockSharesAuthorized,PrepaidExpenseAndOtherAssetsCurrent,PrepaidInsurance,PrepaidTaxes,ProceedsFromIssuanceInitialPublicOffering,ProceedsFromIssuanceOfCommonStock,ProceedsFromIssuanceOfPreferredStockAndPreferenceStock,ProceedsFromIssuanceOfWarrants,ProceedsFromRelatedPartyDebt,RepaymentsOfRelatedPartyDebt,ResearchAndDevelopmentExpense,RetainedEarningsAccumulatedDeficit,ShareBasedCompensation,ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate,ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum,ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum,ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum,ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice,ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice,SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1,SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares,StockholdersEquity,StockIssued1,StockIssuedDuringPeriodValueNewIssues,TemporaryEquityCarryingAmountAttributableToParent,TemporaryEquityParOrStatedValuePerShare,TemporaryEquitySharesAuthorized,TemporaryEquitySharesIssued,TemporaryEquitySharesOutstanding,WeightedAverageNumberOfShareOutstandingBasicAndDiluted,IncreaseDecreaseInDueFromRelatedPartiesCurrent,OperatingIncomeLoss,OtherExpenses,ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2021-03-31,2021-06-21,10-Q,"ANEBULO PHARMACEUTICALS, INC.",ANEB,CIK0001815974,USD,82027.0,,211139.0,,,83526.0,47407.0,,4291475.0,3898745.0,,3307083.0,3307083.0,,0.001,22800000.0,12982500.0,12982500.0,12983.0,,,,,,,,8208393.0,-0.68,,,,,,501700.0,,279093.0,-555832.0,,,,,,,3701.0,,,10751559.0,4291475.0,293166.0,,,,-555832.0,-8764225.0,,,552131.0,,,,7125.0,,3609.0,,,8208393.0,,,591662.0,,23070.0,,,,,,,273038.0,-9532345.0,,,,,,,383418.0,0.1895,,2038688.0,1586904.0,0.8986,,764467.0,301554.0,-9435836.0,,,2975752.0,0.0001,8943906.0,2047500.0,2047500.0,12982500.0,,,,,,
2021-06-30,2021-09-22,10-K,"ANEBULO PHARMACEUTICALS, INC.",ANEB,CIK0001815974,USD,110048.0,,131585.0,131585.0,9923.0,60032597.0,199947.0,604404.0,21653491.0,,19985645.0,,19985645.0,16960665.0,0.001,40000000.0,23344567.0,23344567.0,23345.0,,797952.0,497171.0,2367000.0,281137.0,19644.0,797952.0,8208393.0,-2.83,0.0,0.21,0.025,0.0,0.185,375000.0,26626710.0,1343755.0,-3613753.0,763025.0,110048.0,-3500.0,109006.0,,1667846.0,11767.0,13053.0,1020.0,241633.0,21653491.0,,26627000.0,21831854.0,-4871189.0,-30252554.0,-38460947.0,-26638801.0,,3613753.0,,,-1344.0,30310.0,,12629.0,821630.0,,8208393.0,0.001,2000000.0,1667846.0,1093101.0,,,20604770.0,,2250000.0,,201286.0,2269998.0,-38644084.0,199947.0,0.0,0.509,0.496,0.0064,0.0013,59664.0,2.18,604404.0,2802420.0,604404.0,2.18,2.18,276642.0,,21411858.0,40060855.0,,,,,,,13612701.0,,,,,,
2021-09-30,2021-11-12,10-Q,"ANEBULO PHARMACEUTICALS, INC.",ANEB,CIK0001815974,USD,493819.0,,113887.0,113887.0,,60066770.0,34173.0,604404.0,20500342.0,,19207743.0,,19207743.0,-777902.0,0.001,40000000.0,23344567.0,23344567.0,23345.0,,,,,,,,,-0.07,,,,,,341111.0,,839826.0,-1554924.0,,383771.0,,-17698.0,,-375247.0,,,,607706.0,20500342.0,,,,-777902.0,-1553395.0,,1529.0,,1554924.0,,24293.0,,8040.0,9880.0,,,,,,,1292599.0,766456.0,,,,,,,,715098.0,-40197479.0,34173.0,,,,,,62664.0,2.18,,2639230.0,604404.0,2.18,,273633.0,,19892636.0,,,,,,,,23344567.0,,,,,,
2021-12-31,2022-02-11,10-Q,"ANEBULO PHARMACEUTICALS, INC.",ANEB,CIK0001815974,USD,42944.0,,7000.0,7000.0,,60161052.0,94282.0,,18963871.0,,18008990.0,,18008990.0,,0.001,40000000.0,23344567.0,23344567.0,23345.0,,,,,,,,,-0.05,,,,,,382504.0,,858186.0,,,,,,,,,,,49944.0,18963871.0,,,,,-1072991.0,,,,1071122.0,,,,5341.0,,,,,,,,954881.0,458708.0,,,,,,,,212936.0,-41270470.0,94282.0,,,,,,81288.0,3.08,,2397469.0,661063.0,2.59,,260467.0,,18913927.0,,,,,,,,23344567.0,,-1071122.0,1869.0,,,
